Compare Regeneron Pharmaceuticals Inc (REGN) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Verisign, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Verisign, Inc. trades at $286.99 (market cap $25.51B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.3× Verisign, Inc.'s market cap, and Verisign, Inc. pays the higher dividend (1.15%). Which is the better fit depends on your goals.
| REGN | VRSN | |
|---|---|---|
Market Cap | $83.43B | $25.51B |
Sector | Health | Technology |
52-Week High | $852.03 | $310.00 |
52-Week Low | $555.51 | $211.49 |
Enterprise Value | $78.14B | $26.82B |
Dividend Yield | 0.46% | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
VeriSign (VRSN) trades at $282.20, down 3.38% on the day, with a bearish technical signal but strong fundamentals including a 49.77% net income margin and record domain registrations. Recent Q2 2026 earnings beat estimates with EPS of $2.38, though Q4 2025 and Q2 2026 missed expectations. The stock faces headwinds from an antitrust lawsuit filed in September 2026, but institutional buying by firms like BlackRock signals confidence.
Outlook is mixed: bullish analyst consensus with a $328.50 price target suggests 16% upside, supported by AI-driven domain growth and a pending .web delegation. Risks include legal overhangs and competitive pressures. The current valuation at a P/E of 30.64 may limit near-term gains unless earnings accelerate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
